Canadian Drug Developer Signs Multi-Year, Million Dollar Plus Contract for OmniComm Systems’ TrialMaster® EDC
Fort Lauderdale, FL, February 11, 2016 - OmniComm Systems, Inc., a global leading provider of clinical data management technology, today announced the signing of a five year agreement with a Canadian pharmaceutical drug developer. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five year term in numerous global trials spanning Phase I to Phase III clinical studies.
TrialMaster was selected after an exhaustive evaluation that included OmniComm and six other leading EDC solution providers to select the replacement for their legacy EDC application. Specific evaluation emphasis was placed on fast study build time, ease of data extraction in submission ready data format, direct patient data entry and a comprehensive feature set. TrialMaster was found superior in all categories when compared to the other six competing EDC technologies. The depth and breadth of functionality, ease of contracting, and a highly responsive executive management team were significant factors in the selection of TrialMaster EDC.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
